Pronounced Differences in the Disposition of Clomipramine Between Japanese and Swedish Patients
Authors:
- Markus JerlingMJMarkus Jerling
- Ylva BöttigerYBYlva Böttiger
- Shin YasudaSYShin Yasuda
- Sachiyo MoritaSMSachiyo Morita
- Leif BertilssonLBLeif Bertilsson
- 1 October 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 19 (5) , 393-400
Abstract
The aim of this study was to compare the disposition of the tricyclic antidepressant clomipramine (C) in Japanese and Swedish patients receiving continuous treatment. Therapeutic drug monitoring data for C and the active metabolite N-desmethylclomipramine (DC) in Japanese patients receiving monotherapy (N = 12) and in those receiving C plus benzodiazepines (BZDs) (N = 96) as well as in Swedes receiving C monotherapy (N = 131) and in those receiving C plus BZDs (N = 43) were used. A population kinetic approach with Bayesian feedback was used to estimate the individual clearance values for C. The relationships between kinetic variables and covariates were evaluated by linear multiple regression. The median (25% and 75% quartiles, respectively) oral clearance of C was 12.7 L/hr (11.6, 30.6) in Japanese patients receiving C monotherapy, 18.1 L/hr (5.6, 31.8) in Japanese patients receiving C plus BZDs, 62.7 L/hr (40.0, 90.6) in Swedish patients receiving C monotherapy, and 56.5 L/hr (34.3, 74.1) in Swedish patients receiving C plus BZDs. When combining all populations in a linear multiple regression, clearance was correlated with ethnic group (p < 0.00001) and age (p < 0.0005), but it was uncorrelated with gender, body weight, and administration of BZDs. The C/DC plasma concentration ratios were 1.08 in Japanese patients receiving C monotherapy, 0.90 in Japanese patients receiving C plus BZDs, 0.51 in Swedish patients receiving C monotherapy, and 0.49 in Swedish patients receiving C plus BZDs. Thus, the lower oral clearance of C in Japanese patients compared with that in Swedish patients is not accounted for by the lower body weight in Japanese patients or by concomitant treatment with BZDs and is therefore likely to be a true ethnic difference. The higher C/DC ratio implicates a more pronounced serotonergic than noradrenergic effect in Japanese patients than in Swedish patients.Keywords
This publication has 26 references indexed in Scilit:
- In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamineBritish Journal of Clinical Pharmacology, 1996
- Polymorphic Drug OxidationCNS Drugs, 1996
- The Emerging Role of Cytochrome P450 3A in PsychopharmacologyJournal of Clinical Psychopharmacology, 1995
- Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patientsPharmacological Research, 1995
- The importance of substrate concentration in determining cytochromes P450 therapeutically relevant in vivoPharmacogenetics, 1994
- Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolismPharmacogenetics, 1993
- Fluvoxamine is a potent inhibitor of cytochrome P4501A2Biochemical Pharmacology, 1993
- Bayesian Parameter Estimation and Population PharmacokineticsClinical Pharmacokinetics, 1992
- Nortriptyline Kinetics in Japanese and AmericansJournal of Clinical Psychopharmacology, 1984
- The bioavailability of oral and parenteral chlorimipramine (anafranil)Progress in Neuro-Psychopharmacology, 1980